JAZZ Stock Jazz Pharmaceuticals plc

$230.26
1d-2.62%5d-4.67%1m+8.63%ytd+35.45%
At close · Nov 20, 4:00 PM ET
After hours $230.62 +0.16% · Nov 20, 4:12 PM ET
52w low $156.9567% of range$266.38 52w high
Price

Today’s call · JAZZ

All live ideas →

4 of 6 technical checks lean bullish

JAZZ is in an uptrend, momentum firm. $234.73 is the level overhead; $228.74 the first support below.

No open idea.From $230.26 the reward-to-risk to $234.73 against $228.74 is 2.9 — below the 3:1 bar.
What would create one:
  • A close above $234.73 on rising volume (breakout).
  • A pullback to $228.74 that holds (entry near support).
Alert me at a level

The brief

Price vs 50-day · abovePrice vs 200-day · above50d vs 200d avg · aboveMACD · bullishRSI momentum · 495-day tape · -4.7%
signalJAZZ’s 50-day average is above the 200-day — long-term trend alignment is bullish.
levelPrice is 1.94% from resistance $234.73 — watch for a break or rejection.
levelFirst support $228.74 is 0.66% below.
volumeVolume is expanding vs its 20-day average.
newsJazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript
newsIambic Provides Business Updates and Third Quarter 2026 Financial Results
All readings
TrendUptrend · above 50-day & 200-day
MomentumRSI 48.8 · MACD bullish
Trend strengthADX 27.3 · strong trend
Location+0.7% vs 50-day MA
52-week range-12% from high · +44% from low
VolatilityATR 9.16 · ~4.0%/day
RSI 14
48.8
MACD
4.40
ADX 14
27.3
ATR 14
9.16
SMA 50
$228.74
SMA 200
$221.86

Levels that matter

$234.73swing zone · 2×+1.9%
$240.5swing zone · 3×+4.5%
$250round+8.6%
$228.74sma 50−0.7%
$225round−2.3%
$221.86sma 200−3.6%

Compare with…

Analyst overview · Nov 15

Jazz Pharmaceuticals (JAZZ) stock analysis, November 15, 2026: bullish medium‑conviction on upside breakout

Jazz Pharmaceuticals closed at $241.55 on November 13, holding above its swing‑zone support of $241.20 while the daily trend follows a weekly uptrend that has kept the price above its 40‑week average. The stock outperformed the S&P 500 over the past 50 days by 6.8% but lagged its healthcare peer XLV by 2.5% in the same period. The balance of evidence points to a bullish stance for the next two to six weeks, though the breakout math falls short of a 3‑to‑1 reward‑to‑risk ratio.

Why it matters

The recent price action reflects a modest rally of roughly 2.9% over the past five days, a move that was largely driven by the stock itself rather than broader market or sector momentum. The S&P 500 rose 2.6% in the same window, while the XLV health‑care ETF gained 2.2%, leaving Jazz with a 0.7% edge over its sector. That edge suggests the market is beginning to price in a relative strength that is not fully explained by macro factors.

Volume on the latest session was 38.4% below its 20‑day average, indicating that the advance has occurred on relatively light participation. The price remains well within its 52‑week range, sitting 7.7% below the high of $261.62 and 71.2% above the low of $141.07. The RSI of 60.8 shows the stock is neither overbought nor oversold, reinforcing a neutral‑to‑positive bias.

Analyst consensus remains strongly positive, with a mean target of $297.59, a low of $220.00 and a high of $330.00. The current price is 18.8% below the mean target, leaving ample upside in the valuation spread. The consensus “strong buy” rating aligns with the bullish technical picture.

Debate among commentators centers on whether the recent rally is sustainable. One side points to the stock’s ability to stay above its swing‑zone support and its outperformance versus the S&P 500, arguing that the weekly trend and the 40‑week average provide a solid foundation. The opposing view highlights the weak volume and the fact that Jazz lags XLV over the 50‑day horizon, suggesting that sector‑specific headwinds could limit further gains. Both arguments rely on the same data points, and the weight of evidence leans toward the bullish side.

What the evidence says

On the long‑term horizon the thesis remains intact: the price is above both its 50‑day ($229.13) and 200‑day ($220.03) simple moving averages, and the stock sits above its 40‑week average, confirming an uptrend that has not been broken.

For the next two to six weeks the balance of evidence leans positive with a medium conviction. The assessment cites two of four conviction points: the daily trend aligns with the weekly uptrend and Jazz is leading the S&P 500 over 50 days. The strongest case against this reading is the lag versus XLV of –2.5% over the same period and the subdued volume, which together keep conviction from rising to high.

Levels that matter

The structure holds above the swing‑zone support at $241.20, a level that has acted as a floor since the recent pullback. A break below $234.73, the next swing‑zone support, would signal the end of the current uptrend according to the picture‑change rule.

The breakout math calls for a daily close above the round level of $250.00 on volume exceeding the 20‑day average. If that occurs, the first target is the 52‑week high of $261.62, offering a reward‑to‑risk of about 1.1 based on a stop at $239.19 (derived from $241.20 minus a quarter of the 14‑day ATR of $8.03). The second target sits at $265.71, a swing‑zone level, with a reward‑to‑risk near 1.5. Because the math does not reach a 3‑to‑1 ratio, a price of roughly $277 would be needed to achieve that threshold.

What would change the picture

A weekly close below $234.73 would break the swing‑zone rule and could shift the outlook toward a downtrend. Additionally, a significant earnings miss on the upcoming November 3 earnings release would provide a non‑price catalyst capable of altering the current narrative.

What to watch

  • November 3 earnings – focus on the headline earnings per share figure.
  • Sector developments – any major regulatory or pricing news affecting the broader healthcare sector could move Jazz before its own earnings.
  • Valuation – the gap between the current price and the mean analyst target of $297.59 remains a key metric for upside potential.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.